This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SCH 619734
Description: Rolapitant is a neurokinin-1 (NK-1) receptor antagonist.
Rolapitant was originally developed by Schering-Plough.
Merck and Schering-Plough
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.
Schering-Plough and OPKO
In October 2009, OPKO Health announced that it has entered into a definitive agreement with Schering-Plough to acquire assets relating to Schering's neurokinin-1 receptor antagonist program. The transaction was completed in November 2009.
Tesaro and OPKO
In December 2010, TESARO and OPKO signed a definitive agreement...See full deal structure in Biomedtracker
Partners: Opko Health Jiangsu Hengrui Medicine Co., Ltd.
Additional information available to subscribers only: